MX2016006894A - Terapia de combinacion que comprende un inhibidor de jak, cdk y pim. - Google Patents

Terapia de combinacion que comprende un inhibidor de jak, cdk y pim.

Info

Publication number
MX2016006894A
MX2016006894A MX2016006894A MX2016006894A MX2016006894A MX 2016006894 A MX2016006894 A MX 2016006894A MX 2016006894 A MX2016006894 A MX 2016006894A MX 2016006894 A MX2016006894 A MX 2016006894A MX 2016006894 A MX2016006894 A MX 2016006894A
Authority
MX
Mexico
Prior art keywords
combination
cdk
jak
treatment
pim
Prior art date
Application number
MX2016006894A
Other languages
English (en)
Inventor
Alexander Cao Zhu
PINZON-ORTIZ Maria
Rong Xianhui
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2016006894A publication Critical patent/MX2016006894A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La presente invención se refiere a una combinación farmacéutica que comprende (a) un compuesto inhibidor de JAK, (b) un inhibidor de CDK, y (c) un compuesto inhibidor de quinasa PIM, y opcionalmente, al menos un portador farmacéuticamente aceptable para uso simultáneo, separado o uso secuencial, en particular para el tratamiento de un neoplasma mieloide o leucemia; una composición farmacéutica que comprende tal combinación; el uso de tal combinación para la preparación de un medicamento para el tratamiento de la neoplasia mieloide o leucemia; un paquete o producto comercial que comprende tal combinación como una preparación combinada para uso simultáneo, separado o secuencial; y a un método de tratamiento de un mamífero, especialmente un ser humano.
MX2016006894A 2013-11-27 2014-11-25 Terapia de combinacion que comprende un inhibidor de jak, cdk y pim. MX2016006894A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361909547P 2013-11-27 2013-11-27
US201462081210P 2014-11-18 2014-11-18
US201462082174P 2014-11-20 2014-11-20
PCT/US2014/067352 WO2015081083A1 (en) 2013-11-27 2014-11-25 Combination therapy comprising an inhibitor of jak, cdk and pim

Publications (1)

Publication Number Publication Date
MX2016006894A true MX2016006894A (es) 2016-08-17

Family

ID=52302307

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016006894A MX2016006894A (es) 2013-11-27 2014-11-25 Terapia de combinacion que comprende un inhibidor de jak, cdk y pim.

Country Status (10)

Country Link
US (2) US20160375024A1 (es)
EP (1) EP3074043A1 (es)
JP (1) JP2016538305A (es)
KR (1) KR20160090814A (es)
CN (1) CN105764528A (es)
AU (3) AU2014354821A1 (es)
CA (1) CA2929620A1 (es)
MX (1) MX2016006894A (es)
RU (1) RU2016125133A (es)
WO (1) WO2015081083A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106336412A (zh) * 2015-07-10 2017-01-18 南开大学 作为cdk4/6抑制剂的2-(n-氧化芳环-2基氨基)-吡咯并嘧啶及嘌呤类化合物
US20210113562A1 (en) * 2018-04-13 2021-04-22 Sumitomo Dainippon Pharma Oncology, Inc. Pim kinase inhibitors for treatment of myeloproliferative neoplasms and fibrosis associated with cancer
JP2022502491A (ja) * 2018-09-25 2022-01-11 インパクト バイオメディシンズ インコーポレイテッドImpact Biomedicines, Inc. 骨髄増殖性疾患の治療法
EP3924351A4 (en) 2019-02-12 2022-12-21 Sumitomo Pharma Oncology, Inc. FORMULATIONS COMPRISING HETEROCYCLIC PROTEIN KINASE INHIBITORS

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY162590A (en) 2005-12-13 2017-06-30 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b] pyridines and pyrrolo[2,3-b] pyrimidines as janus kinase inhibitors
WO2010020675A1 (en) * 2008-08-22 2010-02-25 Novartis Ag Pyrrolopyrimidine compounds as cdk inhibitors
PT2344474E (pt) * 2008-09-02 2015-12-28 Novartis Ag Derivados de picolinamida como inibidores de cinase

Also Published As

Publication number Publication date
JP2016538305A (ja) 2016-12-08
WO2015081083A1 (en) 2015-06-04
RU2016125133A (ru) 2018-01-09
AU2014354821A1 (en) 2016-05-26
US20180071296A1 (en) 2018-03-15
KR20160090814A (ko) 2016-08-01
EP3074043A1 (en) 2016-10-05
US20160375024A1 (en) 2016-12-29
AU2018256668A1 (en) 2018-11-22
CA2929620A1 (en) 2015-06-04
CN105764528A (zh) 2016-07-13
AU2017245332A1 (en) 2017-11-02

Similar Documents

Publication Publication Date Title
PH12018500097A1 (en) Combination of pd-1 antagonist with an egfr inhibitor
PH12017500281A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
TN2015000278A1 (en) Autotaxin inhibitors
MY176235A (en) Compounds that inhibit mcl-1 protein
PH12016500933A1 (en) Novel combination treatment for acute myeloid leukemia (aml)
MX2019009853A (es) Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres.
PH12016501830A1 (en) Inhibitors of c5a for the treatment of viral pneumonia
MX366899B (es) Nuevos compuestos.
JO3784B1 (ar) الاستخدام المشترك للاجسمام المضادة pd-1 ومضادات m-csf في علاج السرطان
GB201118656D0 (en) New compounds
AU2018256668A1 (en) Combination therapy comprising an inhibitor of JAK, CDK and PIM
MX2018000419A (es) Derivados de amida sustituida que tienen actividad multimodal contra el dolor.
JO3122B1 (ar) مشتقات إسترا-5،3،1(10)، 16- تترايين-3- كربوكساميد، عمليات لتحضيرها، مستحضرات دوائية تشتمل عليها واستخدامها لتحضير أدوية
MX2016001683A (es) Combinaciones de inhibidores de quinasa pim.
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
MX2015004362A (es) Derivados de ketamina.
PH12016500978A1 (en) Piperazine derivatives having multimodal activity against pain
MX2016006604A (es) Derivados de piperidina con actividad multimodal contra el dolor.
MX2017006437A (es) Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor.
MX2021010041A (es) Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt.
MX2016006603A (es) Compuestos piperidinicos con actividad multimodal contra el dolor.
MX2017014776A (es) Combinacion farmaceutica de everolimus con dactolisib.
MX362905B (es) Tratamiento de combinacion.
MY193423A (en) Oxadiazaspiro compounds for the treatment of drug abuse and addiction
MX362533B (es) Combinacion de analogos de somatostatina con inhibidores de 11-beta-hidroxilasa.